Found 46 matching trials
Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above PHASE2 This is a multi-center, open-label phase II study to assess the efficacy of...
Show More Status
Active Not Recruiting
Location
Rutgers Cancer Institute of New Jersey
Learn More & Join Trial
Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma PHASE2 This phase II trial compares the impact of brentuximab vedotin and nivoluma...
Show More Location
Multiple Locations
Learn More & Join Trial
Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease. PHASE2 This is a single-arm, open-label, multicenter, clinical trial to evaluate t...
Show More Location
ASST Spedali Civili di Brescia
Learn More & Join Trial
Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL PHASE2 Children, adolescents, and young adults (CAYA) with relapsed/refractory (R/...
Show More Location
New York Medical College
Learn More & Join Trial
BV After Allogeneic Hematopoietic Stem Cell Transplantation PHASE2 Despite a high recovery rate with chemotherapy and radiation therapy treatm...
Show More Location
Caen University Hospital
Learn More & Join Trial
A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) PHASE2 This is a study incorporating brentuximab vedotin and dose attenuated ritux...
Show More Status
Active Not Recruiting
Location
James P. Wilmot Cancer Institute, University of Rochester Medical Center
Learn More & Join Trial
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides PHASE1 This is an open label, single center, non-randomized dose de-escalation pha...
Show More Location
University of Alabama at Birmingham
Learn More & Join Trial
BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas PHASE3 There is no data comparing the effectiveness of the 4 most relevant first-l...
Show More Status
Enrolling By Invitation
Location
Multiple Locations
Learn More & Join Trial
Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin N/A The goal of this is study is focusing on assessment of patient-reported out...
Show More Location
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
Learn More & Join Trial
BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant PHASE2 A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with B...
Show More Location
Institut Català D'Oncologia - Hospital Germans Trias I Pujol
Learn More & Join Trial